Swathi Ramakrishnan
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
-
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
Papers in
-
- Epigenetics and DNA Methylation 13
- Histone Deacetylase Inhibitors Research 7
- Renal and related cancers 4
- Protein Degradation and Inhibitors 2
-
- Prostate Cancer Treatment and Research 7
- Renal cell carcinoma treatment 6
- Co-authors
- Роберто Пили (18 shared papers)Leigh Ellis (10 shared papers)Kiersten Marie Miles (9 shared papers)Li Shen (8 shared papers)Sheng‐Yu Ku (9 shared papers)Eric Ciamporcero (7 shared papers)Paula Sotomayor (4 shared papers)Michael J. Ciesielski (2 shared papers)
- Journals
- Molecular Cancer Therapeutics (3 papers)PLoS ONE (3 papers)Cancer Research (2 papers)The Prostate (2 papers)Oncotarget (2 papers)
- Partner nations
- United StatesItalyArgentina
In The Last Decade
Swathi Ramakrishnan
27 papers receiving 894 citations
Peers
Comparison fields: 5 of 77
- Oncology 251
- Molecular Biology 628
- Immunology 180
- Cancer Research 126
- Pulmonary and Respiratory Medicine 256
Countries citing papers authored by Swathi Ramakrishnan
This map shows the geographic impact of Swathi Ramakrishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swathi Ramakrishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swathi Ramakrishnan more than expected).
Fields of papers citing papers by Swathi Ramakrishnan
This network shows the impact of papers produced by Swathi Ramakrishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swathi Ramakrishnan. The network helps show where Swathi Ramakrishnan may publish in the future.
Co-authors
The 25 scholars most cited alongside Swathi Ramakrishnan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 167 | |
| 2 | 2015 | 108 | |
| 3 | 2014 | 77 | |
| 4 | 2014 | 74 | |
| 5 | 2019 | 74 | |
| 6 | 2013 | 57 | |
| 7 | 2014 | 56 | |
| 8 | 2014 | 48 | |
| 9 | 2016 | 35 | |
| 10 | 2017 | 27 | |
| 11 | 2013 | 24 | |
| 12 | 2011 | 17 | |
| 13 | 2011 | 17 | |
| 14 | 2013 | 17 | |
| 15 | 2019 | 17 | |
| 16 | 2013 | 17 | |
| 17 | 2019 | 15 | |
| 18 | Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice. | 2018 | 13 |
| 19 | 2014 | 11 | |
| 20 | 2019 | 10 |
About Swathi Ramakrishnan
Swathi Ramakrishnan is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Surgery, Oncology and Cancer Research, having authored 28 papers that have together received 902 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (13 papers), Prostate Cancer Treatment and Research (7 papers), Histone Deacetylase Inhibitors Research (7 papers), Bladder and Urothelial Cancer Treatments (6 papers), Renal cell carcinoma treatment (6 papers), Renal and related cancers (4 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Oncology (251 citations), Molecular Biology (628 citations), Immunology (180 citations), Cancer Research (126 citations) and Pulmonary and Respiratory Medicine (256 citations). Swathi Ramakrishnan has collaborated with scholars based in United States, Italy and Argentina. Frequent co-authors include Роберто Пили, Leigh Ellis, Kiersten Marie Miles, Li Shen, Sheng‐Yu Ku, Eric Ciamporcero, Paula Sotomayor, Michael J. Ciesielski, Remi Adelaiye‐Ogala and Robert A. Fenstermaker. Their work appears in journals such as Molecular Cancer Therapeutics, PLoS ONE, Cancer Research, The Prostate and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.